Promising breast cancer combo trial pulled before it began
NCT ID NCT07134556
First seen Jan 04, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study aimed to test a combination of three drugs (zimberelimab, domvanalimab, and sacituzumab govitecan) as a first treatment for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative breast cancer). The goal was to see if the combination could shrink tumors and improve outcomes. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.